Immupharma PLC First Cancer Patients in New Trial Begin Dosing (1519N)
September 26 2012 - 2:01AM
UK Regulatory
TIDMIMM
RNS Number : 1519N
Immupharma PLC
26 September 2012
FOR IMMEDIATE RELEASE 26 September 2012
ImmuPharma plc
Cancer programme IPP-204106 progresses into further clinical
trials
First cancer patients in new trial begin dosing
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the
"Group"), the specialist drug discovery and development company, is
pleased to announce that its cancer programme IPP-204106 has begun
further clinical trials with the next generation of "polyplexed
Nucant".
The first patients have started dosing in this new Phase I/II
clinical trial.This "polyplexed Nucant" formulation has shown an
impressive efficacy of about 10 times over the previous Nucant
version in pre-clinical cancer models and represents a new
discovery in that it combines the previous IPP-204106 Nucant
version with a specific excipient that forms micro/nano structures.
IPP-204106 has a novel mechanism of action aimed at preventing
proliferation, inducing apoptosis and also controlling
angiogenesis.
ImmuPharma has made promising progress with its anti-cancer
nucleolin antagonist ("Nucant") peptide programme. Having received
approval from the French regulatory authorities, Agence Francaise
de Securite Sanitaire des Produits de Sante (AFSSAPS) it initiated
an initial Phase I dose ranging tolerability and safety study in
three hospitals in France which is now completed. Patients were
suffering from different types of cancer including breast, lung and
bladder cancers which had all metastasised. No serious drug related
adverse events were reported. 6 out of the 14 patients had a proven
stabilization and for 2 out of the 6 the stabilization lasted for
more than 6 months.
For this next Phase I/II study based on the next generation
"polyplexed Nucant", it is planned to re-evaluate the safety in a
preliminary Phase I dose ranging tolerability study with the new
formulation (first dose level about to be completed shortly)
followed by a Phase II efficacy study designed to treat various
cancers in approximately 30 patients to identify appropriate
biomarkers. This trial will be conducted in three hospitals in
Europe including the prestigious Institute Jules Bordet, an
Integrated Multidisciplinary Centre which is the only autonomous
hospital in Belgium totally dedicated to cancer. Our further
intention is to conduct follow-up studies on patients showing the
appropriate biomarkers with glioblastoma (brain tumour), metastatic
melanoma, and pancreatic cancer where nucleolin plays a key
role.
Recent scientific publications have demonstrated that by
interfering with the pathway of nucleolin and other related
membrane proteins, a strong growth inhibition of cancer cells as
well as a strong induction of apoptosis was observed confirming
initial results. In May 2011, IPP-204106 (also referred to as N6L)
was chosen to feature on the front cover of 'Cancer Research', a
prestigious medical journal of the American Association for Cancer
Research. The article was entitled 'A Simple Approach to Cancer
Therapy Afforded by Multivalent Pseudopeptides That Target
Cell-Surface Nucleoproteins', and was authored by a number of
researchers working at or with the CNRS, the research institution
with which ImmuPharma is collaborating.
Dr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief
Scientific Officer, commented: "The clinical development of our
cancer programme continues to be a key priority for ImmuPharma. It
is therefore extremely encouraging to see the first patients dosed
in this new trial. The improved formulation of the "polyplexed
Nucant" is a great achievement for both ImmuPharma and our partner,
the CNRS, and further strengthens our position in this field."
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Dr Robert Zimmer, President +33 389 66 13 20
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Lisa Baderoon, Head of Investor Relations +44 7721 413 496
Buchanan +44 20 7466 5000
Mark Court
Panmure Gordon & Co +44 20 7459 3600
Andrew Burnett, Fred Walsh
Cenkos Securities +44 20 7397 8900
Stephen Keys, Camilla Hume (Corporate
Finance)
Andy Roberts (Sales)
Espirito Santo Investment Bank +44 20 7456 9191
James Bromhead, Richard Crawley
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. ImmuPharma was founded and
is led by a commercially focused Board and management team with
extensive experience. www.immupharma.com
Institut Jules Bordet
The Institute Jules Bordet, an Integrated Multidisciplinary
Center, is the only autonomous hospital in Belgium totally
dedicated to cancer. It covers both cancer screening and clinical
care, is involved in research activities and is at the same time a
teaching hospital at a high level.
The smooth cooperation between these three activities presents
an original aspect and an important plus for the approach to the
disease.
The original aspect of oncological practice at the Institut
Jules Bordet is based upon the truly multidisciplinary
therapeutical approach, reinforced by a single patient file that is
used by all physicians regardless of their specialty. This file is
present at all consultations and hospitalizations and collects all
medical information on the patient. After establishment of the
diagnosis, decisions about treatment are taken by common agreement,
by a collective reflexion of surgeons, radiologists and internists,
based upon the most modern therapeutical techniques.
The development of today's cancerology would not have been
possible but for an intense laboratory and clinical research.
The "Laboratory for Research and Clinical Investigation"is
pursuing fundamental research, especially in the field of
hematology, mammary cancerology, on melanome and pulmonary cancer
etc, activities that have led to hundreds of scientific
contributions recognized on an international level.
A fundamental aspect of the Institute Jules Bordet is the close
integration of research and practical oncology; as a consequence
clinical research is permanently present in the treatment the
physicians apply. A number of these clinical research programs are
carried out in cooperation with national and international centers,
especially in the framework of the EORTC (European Organization for
Research and Treatment of Cancer) that was founded at the Institute
Jules Bordet in 1964.
Academically and in the framework of the missions entrusted to
the Institute Jules Bordet by the Université Libre de Bruxelles,
the Institute has gained a reputation for the quality of its
teaching of graduate and post-graduate courses. Every year the
Institute forms and trains several oncologists who later practise
their specialities in hospitals of Belgium as well as young
researchers who will return to their respective hospitals to make
use of their newly acquired expertise.
The Institute Jules Bordet distinguishes itself by its vocation
as an integrated multidisciplinary center, developing the most
recent approach and therapies based on active research, thus
radiating both on the national and the international level.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUVORRUKAKUUR
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024